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HPV and cancer  
Papillomaviruses were the first infectious agents to be unequivocally associated with 
tumour formation. While studies had linked animal  Papillomavirus infection to induction of 
warts and of cutaneous cancer, human papillomaviruses proved extremely difficult to work 
with as they could not productively infect cells in culture, and therefore there was little 
material available to support serology and pathogenesis studies and test hypotheses 
concerning their oncogenicity, and it was unclear whether there was just one or a whole 
family of human papillomaviruses..  Electron microscopy studies confirmed that human skin 
and genital warts contained virus particles similar in morphology to those found in rabbit 
warts, but as human skin warts “never” turned malignant, there was no evidence that 
human papillomaviruses might be involved in malignancy.  
Prof Harold zur Hausen was nevertheless intrigued by the epidemiology of cervical cancer, 
which had long suggested an association of this cancer with sexual activity, and by the 
occasional malignant transformation of giant genital warts, which were clearly transmitted 
sexually. Development of tools for DNA analysis in the 1970s made it possible for his team 
to examine genital lesions including genital cancers for DNA homologous with the HPV DNA 
found in genital warts.  These studies eventually revealed that there was genetic material 
partly homologous with that of wart papillomaviruses  in  cervical cancer and precancerous 
lesions(1;2).  These findings, initially greeted with some scepticism, were eventually 
replicated by many teams, and during the 1980s there was increasing acceptance that 
papillomaviruses were likely causative agents for at least some anogenital cancer.  This work 
led to the award of the Nobel Prize for Physiology and Medicine in 2008.   Careful 
epidemiological work by many groups world wide has subsequently established that of the 
over 200 now known human papillomaviruses some 20 are associated with anogenital 
cancer(3), and that practically all cervical cancer and a substantial proportion of other 
anogenital squamous cancers are a consequence of persisting infection with one or more so 
called “high risk” HPV genotypes.  From early studies, it was clear that two type,  HPV16 and 
HPV18, were particularly associated with cervical cancer, and it is now accepted that across 
the globe approximately 70% of cervical cancer is attributable to persistent infection with 
one of these viruses.  Further, the relative risk of cancer given infection with these two 
viruses is significantly higher than for other genital HPV infections, perhaps because of their 
better ability to persist, to suppress immune function locally, and to promote induction and 
fixation of genetic errors within replicating epithelial cells.  
Preclinical studies leading to HPV vaccine development 
Recognition that HPVs contributed to cervical cancer renewed interest during the 1980s in 
the study of the pathogenesis of HPV associated cell proliferation, and of the host  immune 
response to this unusual viral infection which, rather than killing infected skin cells, enabled 
them to proliferate and survive better than  uninfected  cells.   However, Papillomavirus 
could still not be propagated in vitro, and research reagents for human papillomaviruses 
were limited to fragments of the viral genome propagated as recombinant plasmids in 
bacteria, the viral  proteins that could be expressed from these in bacteria, and antibodies 
raised to these proteins in animals. These reagents allowed further progress on the 
understanding of viral pathogenesis.   Research was in large part undertaken with bovine 
papillomaviruses, a relatively abundant source of viral material. However nothing 
resembling the Papillomavirus itself had been produced in vitro.  A  fortuitous meeting  that 
I had in 1989 in Cambridge England with the late Dr Jian Zhou, when we were both visiting 
the lab of Dr Lionel Crawford, led us to use some new molecular biology techniques 
developed by Dr Zhou to try to make a Papillomavirus in vitro. Our initial interest was more 
in how Papillomavirus worked as a virus, and how it was seen by the immune system, than 
in whether we could make a vaccine, for at that time the connection between HPV infection 
and cervical cancer was still subject to debate. There was a feeling that cervical cancer was a 
common outcome from a rare virus infection, rather than, as we now recognise, a rare 
outcome of persistence of infection with a common infectious agent.   These considerations 
and the possibility that the virus involved was oncogenic hindered enthusiasm for vaccine 
development.   However, we needed to make the virus capsid, or coat, to make a virus in 
vitro.  We chose to attempt this using a clone of HPV16 derived from a clinical lesion (a 
fortunate choice) and expressed using a viral vector in epithelial cells (another fortunate 
choice).   When we didn’t get much protein, we experimented with whether we were 
starting the translation of the gene at the correct site and (again a fortunate choice) located 
another potential start site somewhat upstream from what seemed the logical start 
position.  These strategies enabled us to produce in vitro for the first time something that 
looked like the virus on electron microscopic examination(4).  While the yield wasn’t great, 
the first electron micrographs of the synthetic virus shell, which had self assembled from the 
capsid protein building blocks, suggested that a vaccine based on this technology might be 
possible.  We and others then refined the expression technology, produced higher yields of 
the virus like particles in better expression systems, and demonstrated that they were 
immunogenic(5-8).  The vaccines available today are based on these virus like particles(4;9), 
empty shells comprising 360 copies of the viral capsid protein L1 which self assemble to look 
like the virus to the immune system.  These virus like particles, or VLPs, are now made in 
yeast or in insect cells.  They  are combined with a mineral adjuvant,  Alum, with or without 
monophosphoryl lipd A, a bacterial cell wall component, to  help stimulate a strong immune 
response(10).  The vaccines currently include either two (HPV16 and HPV18)  or four (HPV 6, 
11, 16, 18) HPV types The two extra types in the quadrivalent vaccine are responsible for 
about 90% of genital warts.  
 Future vaccines may contain more HPV types but will likely continue to be based on 
virus like particles. VLP based vaccines incorporating multiple HPV types are currently in 
clinical trial.  However, other potential  strategies in preclinical development that may 
eventually reach the clinical are worth noting.  VLPs are assembled from 72 copies of a basic 
building block, the pentamer, which is assembled from 5 L1 molecules, and many of the 
neutralising epitopes presented by the VLP are also presented by the pentamer.   Thus 
simpler vaccines based on pentamers have been suggested(11), though no simple process 
for their production and purification has yet been promulgated.   An alternative vaccine 
strategy is based on the minor capsid protein, L2, which includes a number of  neutralising 
epitopes.  While the virus neutralisation potency of antisera raised against whole length L2 
does not appear as great as for antisera raised against intact L1 capsids, some L2 epitopes 
are shared across many HPV types and a vaccine incorporating these epitopes  together 
with immunogenic carrier protein  may therefore provide extended coverage against the 
HPV types not included in VLP based vaccines(12;13).   
Clinical Vaccine development studies 
Production and testing of virus like particle based Papillomavirus vaccines was undertaken 
commercially from the late 1990s by two pharmaceutical companies, Merck and GSK.  Initial  
trials to demonstrate the safety and efficacy of vaccines designed to prevent infection with 
genital HPV infections and also to prevent the premalignant consequences of these 
infections were  undertaken in young  sexually active women, though more recently studies 
have been extended to include older women, and men. .Phase 1 studies  are designed to 
demonstrate safety and immunogenicity in human subjects, and Phase 2 studies extended 
these data to include data on prevention of infection with relevant HPV types.  Pivotal 
licensing studies address efficacy in prevention of HPV associated disease, including cervical 
and other anogenital pre-cancer (CIN2,3) and, for the quadrivalent vaccine,  genital warts.  
Subsequent phase 4 post marketing  studies have addressed efficacy in particular target 
populations, and duration of protection. 
 
Phase 1 studies, in subjects with and without HPV infection, confirmed the safety and 
immunogenicity of VLP-based vaccines, given intramuscularly with or without adjuvant(14-
16). Three administrations of VLPs with adjuvant induce peak antibody levels at least 10 
times those seen in subjects naturally infected with HPV, and levels of antibody above those 
produced by natural infection have been sustained for at least 8 years post vaccination.  
 
Phase 2 studies (17-19) further addressed immunogenicity.  They also tested ability to 
prevent infection in women naïve to the HPV types in the administered vaccine at 
recruitment, as assessed by failure to detect of HPV DNA in genital samples, and by absence 
of serum antibody to viral capsids of the relevant type.  These studies have shown nearly 
100% efficacy of both the bivalent and the quadrivalent vaccines in prevention of acquisition 
of HPV infections caused by the types present in the vaccines,  amongst sexually active 
young  women.  Phase 3 studies(20-25) have demonstrated near 100% efficacy in “according 
to protocol analyses”  at preventing HPV associated anogenital disease due to vaccine HPV 
types, in young sexually active women, with efficacy data now extended to 4-5 years in most 
studies.  In these studies, if a new cytological or clinical abnormality was detected which 
included a vaccine HPV DNA type, even if other HPV types were also present in the same 
lesion, the vaccine HPV type was held to be causal.  This interpretation biases study results 
away from effectiveness, and may be responsible for the few cases of disease associated 
with vaccine HPV types in these studies, as infection with multiple HPV types are now 
increasingly recognised.  For the phase III efficacy studies, young sexually active women 
were recruited whether or not they had prior HPV infection, so long as they did not have, or 
have a history of, anogenital disease that might be HPV related.  The studies therefore 
included many women infected with vaccine HPV types at recruitment.   Immunisation did 
not appear to impact on the natural history of  these existing HPV infections, which 
regressed or progressed at similar rates in vaccine and placebo recipients(26;27). In 
consequence, vaccine efficacy is much less in “intention to treat” analyses of prevention of 
all HPV related disease, particularly where these included the 30% of disease due to non 
vaccine HPV types, as well as women already infected with a vaccine HPV type but without 
disease at recruitment.    
 
In the major efficacy studies, immunisation with HPV 16 and HPV18  provided some 
protection against infection with high risk HPVs of other types, and against disease 
attributable to these infections.   In a pivotal trial of a bivalent HPV16/18 vaccine, significant 
protection was seen against HPV45 infection, and partial protection against HPV33 
infection(24). For the quadrivalent HPV 6/11/16/18 vaccine, generally HPV naïve subjects 
showed some protection against new anogenital pre-malignancy (CIN 2/3 and AIS)  
associated with 10 non vaccine HPV  types(28).  In each of these studies, actual case 
numbers were quite low, and the true degree of protection therefore hard to assess 
accurately – however the overall efficacy would not be sufficient to alter current clinical 
practice and the need to continue assessing women for cervical pre-cancer through 
conventional screening.  Nevertheless field effectiveness in a vaccine population can be 
inferred from the significant  reduction in genital wart disease observed amongst the target 
vaccine female population in Australia(27;29) where up to 50% coverage has been achieved 
in 18-25 year olds.  
Vaccine Safety 
 
Adverse events after vaccination are assessed from the placebo controlled efficacy studies. 
However, rare events can be assessed effectively only through post marketing surveillance.   
In the placebo controlled studies, local reactogenicity at the site of immunisation and 
systemic malaise was more common than with placebo, but was generally mild and did not 
lead to discontinuation of vaccination.  No serious adverse events were attributable to 
vaccination in the placebo controlled trials.  
  
Over 40 million doses of the quadrivalent vaccine have been delivered to young women 
subsequent to vaccine licensure.  According to the vaccine adverse events reporting service, 
no rare, serious events have been seen with more frequency in vaccine recipients than 
might be expected in an unvaccinated age matched community(30).  Fainting after 
vaccination is the most commonly reported event.   HPV vaccines also seems safe in 
pregnancy, with no increased frequency of adverse pregnancy outcomes. While vaccination 
during pregnancy is not recommended, women who become pregnant while undergoing 
vaccination can be reassured that there is unlikely to be any consequence for the 
pregnancy.  Allergic reactions likely attributable to vaccination are rare, with reported 
frequency of 1 -2 per million vaccine doses delivered(31).  
 
Duration of protection 
 
Most viral vaccines work by inducing neutralising antibody to conformational determinants 
on the surface of the virion.  Antibody to conformational determinants on the 
Papillomavirus capsid is sufficient to convey protection against challenge with live 
Papillomavirus when passively transferred in either a dog or a rabbit model, and, somewhat 
surprisingly, serum IgG antibody seems sufficient to convey protection.  
 
A surrogate marker for virus induced protection against infection would be useful for 
assessing duration of protection post immunisation.  There are no standardised assays for 
antibody to HPV virions through though the World Health Organisation in collaboration with 
the National Centre for Biological Standards is attempting to produce one for HPV16.  
Antibodies to HPV are measured in human serum in a range of in vitro and in vivo assays(32-
35).  Each assay measures different specificities of antibody, and a different proportion of 
the total virus neutralising capacity of a serum, and thus direct comparisons of antibody 
titre are only valid for antibody to one virus type, measured in one assay.  
 
Antibody assays have nevertheless been used as bridging assays for the introduction of 
vaccine into age groups where new infection with HPV is uncommon, including male and 
female children aged 9-15(36), who produce on average higher levels of antibody than the 
16-24 year old women in whom vaccine efficacy studies were undertaken, and  in women 
aged 25-45, whose antibody response is on average somewhat lower.  The quadrivalent HPV 
vaccine has been shown at least 90% effective at preventing new infections with HR HPVs in 
25-45 year old women(37) . 
 
Duration of protection following vaccination can also be inferred from serology studies. 
Antibody levels peak after three doses of vaccine at levels at least 20 times higher than 
those seen after natural infection, and fall significantly during the first two years after 
immunisation, and then remain fairly constant out to five years, at a level well above that 
seen with natural infection(38), and these levels are associated with continuing protection 
against infection.  Further, immunological memory is retained, as a single re-immunisation 
five years after the primary immunisation results in a substantial boost to antibody titres,  
not seen in non-immune subjects(39).   These data can be modelled to suggest that 
protection from these vaccines is likely to be long lasting.   
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